Recurrent Head and Neck Squamous Cell Carcinoma Terminated Phase 1 / 2 Trials for Cetuximab (DB00002)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Terminated1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01602315A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaTreatment